Drugs / PF-02413873
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00857571 | Apr → May 2009 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00800618 | Nov 2008 → Jun 2009 | endometriosis | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-02413873 | “Single oral dose of 150 mg of PF-02413873 suspension” NCT00857571 ↗ |
| Route | Oral | “100 mg of PF-02413873 oral suspension once daily for 14 days” NCT00800618 ↗ |